Aldred MA, Huang Y, Liyanarachchi S, Pellegata NS, Gimm O, Jhiang S et al.. Papillary and follicular thyroid carcinomas show distinctly different microarray expression profiles and can be distinguished by a minimum of five genes. J Clin Oncol 22: 3531-3539

University of Cambridge, Cambridge, England, United Kingdom
Journal of Clinical Oncology (Impact Factor: 18.43). 10/2004; 22(17):3531-9. DOI: 10.1200/JCO.2004.08.127
Source: PubMed


We have previously conducted independent microarray expression analyses of the two most common types of nonmedullary thyroid carcinoma, namely papillary thyroid carcinoma (PTC) and follicular thyroid carcinoma (FTC). In this study, we sought to combine our data sets to shed light on the similarities and differences between these tumor types.
Microarray data from six PTCs, nine FTCs, and 13 normal thyroid samples were normalized to remove interlaboratory variability and then analyzed by unsupervised clustering, t test, and by comparison of absolute and change calls. Expression changes in four genes not previously implicated in thyroid carcinogenesis were verified by reverse transcriptase polymerase chain reaction on these same samples, together with eight additional FTC tumors.
PTCs showed two distinct groups of genes that were either over- or underexpressed compared with normal thyroid, whereas the predominant changes in FTCs were of decreased expression. Five genes could collectively distinguish the two tumor types. PTCs showed overexpression of CITED1, claudin-10 (CLDN10), and insulin-like growth factor binding protein 6 (IGFBP6) but showed no change in expression of caveolin-1 (CAV1) or -2 (CAV2); conversely, FTCs did not express CLDN10 and had decreased expression of IGFBP6 and/or CAV1 and CAV2.
PTC and FTC show distinctive microarray expression profiles, suggesting that either they have different molecular origins or they diverge distinctly from a common origin. Furthermore, if verified in a larger series of tumors, these genes could, in combination with known tumor-specific chromosome translocations, form the basis of a valuable diagnostic tool.

Full-text preview

Available from:
  • Source
    • "It has been reported that several kinds of tumors have relation with up-regulation of claudins. For example, claudin-3 and claudin-4 were expressed at high levels in endometrioid adenocarcinoma [19] and prostate cancer [20]; claudin-10 expression was up-regulated in hepatocellular carcinoma [21] and thyroid papilloma [22]; claudin-2 has been reported to be up-regulated in thyroid cancer and endometrial cancer [23]. Claudins have also been shown to promote tumor invasion by the activation of MMPs [5,11,12]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Tight junctions (TJs) are mainly composed of claudins, occludin, and tight junction adhesion molecules (JAM). The invasive and metastatic phenotype of highly invasive cancer cells has been related to abnormal structure and function of TJs, and with expression of activated matrix metalloproteinases (MMPs). The relevance of these mechanisms responsible for the invasion and metastasis of ovarian carcinoma is unclear. Similarly, it is not known if the expression of claudin-6, occludin and MMP2 is related with the clinical properties of these tumors. Expression of claudin-6, occludin, and MMP2 was detected in samples of human ovarian cancer tissues by immunohistochemistry and correlated with the clinical properties of the tumors. The positive expression rates of claudin-6 and MMP-2 were higher in ovarian papillary serous carcinomas than in ovarian serous adenomas (P <0.05). There were no differences in the expression of occludin (P > 0.05). The expression of claudin-6 and occludin in ovarian cancer was not correlated with patient age, pathological grade, clinical stage, and metastasis (P > 0.05). MMP-2 expression was enhanced with increased clinical stage and metastasis (P <0.05), but was unrelated to patient age or tumor grade (P > 0.05). There were no apparent correlations between expression of claudin-6, occludin and MMP-2 in ovarian cancer tissue (P > 0.05). Our data suggest, for the first time, that the claudin-6 and MMP-2 are up-regulated in ovarian papillary serous carcinomas, MMP-2 expression was enhanced with increased clinical stage and metastasis. Claudin-6 and MMP-2 may play a positive role in the invasion and metastasis of ovarian cancer.Virtual slides: The virtual slide(s) for this article can be found here:
    Diagnostic Pathology 11/2013; 8(1):190. DOI:10.1186/1746-1596-8-190 · 2.60 Impact Factor
  • Source
    • "1 ) . Similarly , microarrays have helped explain the develop - ment of benign pheochoromocytomas , medullary thyroid cancers , and skeletal abnormalities in multiple endocrine neoplasia syndromes ( Jain et al . , 2004 ) and have identi - fied gene expression differences in papillary and follicular thyroid cancers that may be useful in diagnosis ( Aldred et al . , 2004 ) ."
    [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: The article aims to introduce nurses to how genetics-genomics is currently integrated into cancer care from prevention to treatment and influencing oncology nursing practice. Organizing Construct: An overview of genetics-genomics is described as it relates to cancer etiology, hereditary cancer syndromes, epigenetics factors, and management of care considerations. Methods: Peer-reviewed literature and expert professional guidelines were reviewed to address concepts of genetics-genomics in cancer care. Findings: Cancer is now known to be heterogeneous at the molecular level, with genetic and genomic factors underlying the etiology of all cancers. Understanding how these factors contribute to the development and treatment of both sporadic and hereditary cancers is important in cancer risk assessment, prevention, diagnosis, treatment, and long-term management and surveillance. Conclusions: Rapidly developing advances in genetics-genomics are changing all aspects of cancer care, with implications for nursing practice. Clinical Relevance: Nurses can educate cancer patients and their families about genetic-genomic advances and advocate for use of evidence-based genetic-genomic practice guidelines to reduce cancer risk and improve outcomes in cancer management.
    Journal of Nursing Scholarship 01/2013; 45(1). DOI:10.1111/j.1547-5069.2012.01465.x · 1.64 Impact Factor
  • Source
    • "UCP1 immunohistochemistry was also performed in serial sections to identify the brown adipocytes. CITED1 was originally identified in a murine melanoma cell line [37] and in human thyroid carcinoma [38], [39]. It has been reported that CITED1 acts as a transcriptional co-activator for estrogen receptor [40]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Brown adipose tissue (BAT) dissipates chemical energy and generates heat to protect animals from cold and obesity. Rodents possess two types of UCP-1 positive brown adipocytes arising from distinct developmental lineages: "classical" brown adipocytes develop during the prenatal stage whereas "beige" or "brite" cells that reside in white adipose tissue (WAT) develop during the postnatal stage in response to chronic cold or PPARγ agonists. Beige cells' inducible characteristics make them a promising therapeutic target for obesity treatment, however, the relevance of this cell type in humans remains unknown. In the present study, we determined the gene signatures that were unique to classical brown adipocytes and to beige cells induced by a specific PPARγ agonist rosiglitazone in mice. Subsequently we applied the transcriptional data to humans and examined the molecular signatures of human BAT isolated from multiple adipose depots. To our surprise, nearly all the human BAT abundantly expressed beige cell-selective genes, but the expression of classical brown fat-selective genes were nearly undetectable. Interestingly, expression of known brown fat-selective genes such as PRDM16 was strongly correlated with that of the newly identified beige cell-selective genes, but not with that of classical brown fat-selective genes. Furthermore, histological analyses showed that a new beige cell marker, CITED1, was selectively expressed in the UCP1-positive beige cells as well as in human BAT. These data indicate that human BAT may be primary composed of beige/brite cells.
    PLoS ONE 11/2012; 7(11):e49452. DOI:10.1371/journal.pone.0049452 · 3.23 Impact Factor
Show more